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Alzheimer’s disease is characterized by deposits of the amyloid b protein (Ab) in the form of senile
plaques and cerebral amyloid angiopathy. Deposition of Ab into these pathological lesions is directed
by step-wise aggregation of Ab into oligomers, protofibrils and mature fibrils. Currently, all therapies
are purely symptom-relieving, and an actual treatment or prevention of AD is still lacking. Since
aggregated forms of Ab are particularly neurotoxic, interference with the process of Ab aggregation is
a long-envisioned target for therapy. Based on the knowledge that both sulfated (macro)molecules and
small synthetic peptides interfere with Ab aggregation, we developed hybrid ligands to target Ab
fibrillization by a combination of peptide-peptide and sulfate-peptide interactions. A series of peptides,
modified at the N-terminus with sulfated linkers, was successfully prepared by solid phase synthesis.
The hybrid ligands were tested using a viability assay and an aggregation assay. Molecular modeling
was applied to explain the binding of the hybrid ligands to Ab42. The hybrid ligands that we designed,
synthesized and evaluated were found to be non-toxic to cells but displayed negligible inhibition of Ab
fibrillization and Ab-mediated cytotoxicity compared to the beta-sheet breaker peptides known today.
Further molecular modeling simulations suggested that the hybrid ligands were incorporated into the
b-sheet structure of Ab aggregates, indicating that the hybrid ligands may bind to Ab but are unable to
inhibit further aggregation. Optimization of the hybrid ligands by reducing hydrogen bond interactions
of the ligand with following Ab proteins might result in ligands, with improved binding to one Ab
protein, that could potentially disrupt further b-sheet formation. This in turn may reduce toxicity of Ab.
Alzheimer’s disease (AD) is a neurodegenerative disorder that is
characterized by a progression from episodic memory problems
to a slow global decline of cognitive function that leaves patients
with end-stage AD bed-ridden and dependent on custodial care.
It affects 10% of the people over the age of 65, and accounts for
approximately 50% of all patients with dementia.1 The current
standard of care for mild to moderate AD includes treatment
with acetylcholinesterase inhibitors to improve cognitive func-
tion. In addition, the common non-cognitive neuropsychiatric
symptoms of AD (such as mood disorder, agitation, and
psychosis) often require extra medication.2 However, these
treatments are purely symptom-relieving, and an actual treat-
ment or prevention of AD is still lacking.
Histopathological features of AD are extensive deposition of
the amyloid b protein (Ab) in senile plaques (SPs) in the cerebral
cortex as well as in the cerebrovascular wall (cerebral amyloid
angiopathy, CAA). This deposition is a result from the conver-
sion of a-helical or random coil Ab to b-sheet, which facilitates
self-aggregation of normally soluble Ab into dimers, trimers,
oligomers, protofibrils and eventually mature insoluble fibrils.3
In addition, the formation of b-sheet-rich aggregates has been
reported to be toxic towards various cultured cerebral cells,
including neurons, cerebrovascular smooth muscle cells and
human brain pericytes.4–7 Taken together, this suggests that Ab
might be involved in the pathogenesis of AD.
An attractive therapeutic strategy for AD is to block the early
steps of misfolding and aggregation of the soluble Ab by using
small molecule drugs. If the peptide interactions are the same in
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oligomers and in larger fibrils, then such molecules could inhibit
both the formation of toxic oligomers and of fibrils. To this end,
several research groups have designed ‘‘b-sheet breakers’’
(BSB).8,9 BSB are based on peptide sequences that specifically
interfere with b-sheets within Ab. Two sets of peptides were
effective BSB, namely the peptides LPFFD (or its analogues
LVFFA or LPYFD) and KLVFF that bind to a region between
amino acids 16 and 22 of Ab.8,10,11 These compounds inhibit Ab-
mediated neurotoxicity10,12 and Ab deposition in vivo and
improve behavioral deficiency induced by Ab deposition.10,12,13
However, a reasonable molar excess compared to the Ab protein
is needed to achieve such a result.10,14,15
It is known that small sulfated and sulfonated molecules have
high binding affinity with Ab, since they are designed to interfere
with glycosaminoglycan/Ab interaction.19 The binding site on Ab
for GAGs likely resides within the cluster of basic amino acids
13–16 of Ab,20 although it remains possible that other domains
within Ab interact with GAGs as well.21 Thus, this might indicate
that the binding site on Ab for the small anionic sulfates and
sulfonates also resides within the same cluster of amino acids.
Covalent linking of two separate ligands to give so-called
hybrid ligands is a powerful general concept to enhance binding
affinity and improve the biological activity compared to the
separate molecules, a strategy that has successfully been used in
medicinal chemistry in the past years.16–18 Increasing the binding
affinity of a BSB peptide to Ab might decrease the molar excess
needed to affect Ab aggregation, toxicity and deposition.
Considering the relative positions of BSB peptides and GAG
binding to Ab (amino acids 16–22 and 13–16 respec-
tively),8,10,20,22,23 it occurred to us that the covalent attachment of
(poly)sulfates with the BSB peptide by a certain linker would
possibly lead to a hybrid with improved binding characteristics
and, thereby, possibly improved characteristics with respect to
inhibition of Ab fibrillization and Ab-mediated cytotoxicity.
Hence, we synthesized Ab ligands that combine pentapeptide-Ab
interaction and sulfate-Ab interaction and evaluated their effects
on Ab aggregation and Ab-mediated cytotoxicity relative to the
separate ligands.
Since BSB peptide KLVFF contains the basic amino acid
lysine (K), which would result in a zwitterionic structure upon
monosulfonylation, BSB peptide LPFFD, lacking a basic amino
acid, was chosen as starting point of our hybrid ligands. The
synthetic route towards several hybrid ligands (3, 4, 5a–5d and
6a–6d) is shown in Fig. 1, and is based on standard Fmoc-based
solid phase synthesis and introduction of a variety of alcohols at
the N-terminus of the pentapeptide, via carbamate or urea
functionality. Because cleavage of C5H10O4-LPFFD-OH (5d (L-
Pro) and 5d0 (D-Pro)) from the Breipohl resin did not result in the
desired compound, likely caused by the harsh cleavage condi-
tions, a 2-chlorotrityl resin was used instead. The milder condi-
tions for cleavage from the 2-chlorotrityl resin successfully
afforded C5H10O4-LPFFD-OH (5d and 5d
0). After cleavage from
the resin, sulfate groups were introduced by sulfonylation of the
alcohol groups under the action of sulfurtrioxide-amine complex.
Using HPLC, a purity of >95% was achieved for all synthetic
sequences. In addition to the hybrid ligands shown in Fig. 1, as
a control peptide Ac-LPFFD-NH2 (7) was also synthesized. Ac-
LPFFD-NH2 (7) is known in literature as iAb5p and is shown to
reduce amyloid plaque formation in a transgenic mouse model.14
In our study, it served as a control to our hybrid ligands in the
biological assays.
Two kinds of assays were used to determine the biological
activity of the hybrid ligands. First of all, hybrid ligands were
screened for in vitro activity in inhibition of amyloid fibril
formation. Fibril formation was quantified with a fluorescence
assay based on the specific binding of thioflavin T (Th-T) to b-
sheet amyloid aggregates.24 By binding to the b-sheets in Ab
aggregates, a fluorescent signal is produced which is proportional
to the amount of fibrils formed. The effect of the hybrid ligands
on b-sheet formation of Ab42 in the first 48 h of incubation was
analyzed and compared to the inhibitory effect of Ac-LPFFD-
NH2 (7) alone. In earlier studies (unpublished data) it became
apparent that co-incubation of (monomeric) Ab with Ac-
LPFFD-NH2 (7) in a molar ratio of 1 : 20 resulted in approxi-
mately 50% inhibition of the aggregation of Ab. Therefore, we
have used this molar ratio to study the hybrid ligands in the
aggregation assay. Secondly, toxicity of Ab in cell culture has
been reported to be related to the formation of b-sheet-rich
aggregates6 and has been used in several studies to screen diverse
compounds to prevent amyloid neurotoxicity. Degeneration of
smooth muscle cells (SMCs) and pericytes by Ab (aggregation) is
a prominent feature of CAA. We, therefore, developed a model
of Ab-mediated degeneration of cultured human brain pericytes
(HBPs) and SMCs.25,26 These cells were isolated from human
brain capillaries and leptomeningeal vessels, respectively, from
control and AD brains obtained at autopsy. In this model the
aggregation of wild-type Ab1–42, is cytotoxic for HBP and SMC
cultures.5 The effect of the hybrid ligands on Ab42-mediated cell
death after 6 days of incubation was analyzed and compared to
the inhibitory effect of Ac-LPFFD-NH2 (7) alone. In earlier
studies (unpublished data) it became apparent that co-incubation
of (monomeric) Ab with Ac-LPFFD-NH2 (7) in a molar ratio of
1 : 5 resulted in approximately 50% inhibition of the cytotoxicity
of Ab. Therefore, we have used this molar ratio to study the
hybrid ligands in the viability assay.
Co-incubation of Ab42 with Ac-LPFFD-NH2 (7) resulted in an
inhibition of the toxicity and aggregation of Ab42 (Fig. 2), which
confirms earlier research.10 However, no significant effect was
found of either hybrid ligand both on toxicity and aggregation of
Ab42. In Table 1 (supporting materials) an overview of the hybrid
ligands and their effects on aggregation and toxicity of Ab42 is
given. Fig. 2 shows a representative figure for all hybrid ligands.
Co-incubation of Ab42 with Ac-LPFFD-NH2 (7) in a molar ratio
of 1 : 20 results in 66% decrease in fluorescent signal (p < 0.01;
Fig. 2A), i.e. Ac-LPFFD-NH2 (7) seems to inhibit the fibril
formation of Ab42, which confirms earlier research.
27 However,
co-incubation of Ab42 with C5H10O4-LPFFD-OH (5d) or the
bissulfonylated analogue C5H8Na2O10S2-LPFFD-OH (6d) in
a molar ratio of 1 : 20 resulted in a fluorescent signal comparable
to the signal of Ab42 alone (Fig. 2A). Incubation of buffer alone
or the compounds themselves did not result in a fluorescent
signal. In addition, a significant difference was observed in cell
death between HBPs treated with 10 mM Ab42 either alone (25%
cell death) or with Ac-LPFFD-NH2 (7; 11.3% cell death; p <
0.001; Fig. 2B) in a molar ratio of 1 : 5 for 6 days, which also
confirms earlier research.10,12 However, again no significant effect
was observed when co-incubating Ab42 with 5d or 6d in a molar
ratio of 1 : 5 for 6 days compared to incubation with Ab42 alone
This journal is ª The Royal Society of Chemistry 2011 Med. Chem. Commun., 2011, 2, 60–64 | 61
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(Fig. 2B). Incubation of the compounds alone resulted in cell
death comparable to control levels. Thus, N-terminal chain
extension of peptide LPFFD with an aliphatic alcohol or sulfo-
nylated alcohols, via urea or carbamate functionality, conse-
quently leads to derivatives with reduced activity with respect to
Ac-LPFFD-NH2 (7) itself.
To find a possible explanation for these results, a molecular
modelingapproachwasappliedtothehybridligands(3,4,5a–5cand
6a–6c) and the NMR structure deposited in RCSB Protein Data
BankundertheIDnumber2BEG28asamodelfortheAb42fibrils(see
supportingmaterials).InearlierstudiesthebindingsiteofLPFFDon
Ab42 was determined
23,29 and we used this binding site to align our
Fig. 1 Synthetic route towards hybrid ligands. Reaction conditions: (a) p-nitrophenylchloroformate and DIPEA in dichloromethane, r.t., 1 h; (b) HO-
X-NH2, N,N-diisopropylethylamine in DMF, r.t., 18 h; TFA/H2O/1,2-ethanedithiol/triisopropylsilane (92.5/2.5/2.5/2.5), r.t., 2 h (3a–3d); (d) HO-X-OH,
1,8-diazabicycloundec-7-ene (DBU) in DMF, r.t., 18 h; TFA/H2O/1,2-ethanedithiol/triisopropylsilane (92.5/2.5/2.5/2.5), r.t., 2 h (5a–5c) or 2-hydroxy-
methyl-1,3-propanediol, DBU in DMF, r.t., 18 h; dichloromethane/TFA/acetic acid (3/1/1), r.t., 1 h (5d); (c,e) sulfur trioxide-trimethylamine in DMF,
50 C, 18 h; sat. aq. NaHCO3, r.t.,18 h (4a–4d and 6a–6d).
Fig. 2 Analysis of the effect of Ac-LPFFD-NH2 (7), C5H10O4-LPFFD-OH (5d) and C5H8Na2O10S2-LPFFD-OH (6d) on Ab-induced cytotoxicity
towards human brain pericytes (HBPs). Effects on aggregation of 50 mM Ab42 for 48 h (A) and cell death in HBP cultures after incubation with 10 mM
Ab42 for 6 days (B) is shown. The concentration of hybrid ligand is shown as the molar ratio of Ab42: hybrid ligand. Co-incubation of Ab42 with Ac-
LPFFD-NH2 (7) in a ratio of 1 : 20 results in 66% decrease in fluorescent signal (p < 0.01; A). However, co-incubation of Ab42 with C5H10O4-LPFFD-
OH or C5H8Na2O10S2-LPFFD-OH in a ratio of 1 : 20 resulted in a fluorescent signal comparable to the signal of Ab42 alone (A). Incubation of buffer
alone or the compounds themselves did not result in a fluorescent signal. In addition, a significant difference was observed in cell death between HBPs
treated with 10 mM Ab42 alone (25% cell death) or with Ac-LPFFD-NH2 (7; 11.3% cell death; p < 0.001; B) in a ratio of 1 : 5 for 6 days. However, no
significant effect was observed when co-incubating Ab42 with C5H10O4-LPFFD-OH or C5H8Na2O10S2-LPFFD-OH in a ratio of 1 : 5 for 6 days
compared to incubation with Ab42 alone (B). Incubation of the compounds alone resulted in a cell death comparable to control levels.
62 | Med. Chem. Commun., 2011, 2, 60–64 This journal is ª The Royal Society of Chemistry 2011
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hybridligandstotheAb42protein.AscanbeseeninFig.S1,aniceb-
pleated sheet was observed when aligning several Ab42 proteins.
Accordingtotheobtainedmodel,itwasrationalizedthataspacerof
threecarbonatomsshouldbesufficienttotargetHis13and/orHis14
intheAb42proteinwithasulfategroupofthehybridligand,Fig.S1.
Based on this insight, our synthetic compounds could simulta-
neously target thebindingdomainsofGAGs (binding toAbamino
acids13–16)andofpentapeptides(bindingtoAbaminoacids16–22).
After alignment, molecular dynamics was performed with the
assumption that the phenylalanine (amino acid 3) of the hybrid
ligand adopts the same orientation as the phenylalanine (amino
acid 18) of the Ab42 protein. Thus, from this initial conformation
for molecular dynamics simulations in water, the energetically
most favorable ‘‘docking’’ conformation was sought. It should be
mentioned that during these calculations the starting configura-
tion will not be the most sampled configuration if it is not
energetically favorable, certainly if the simulation time is long
enough. From these calculations it became apparent that,
although both phenylalanines of the hybrid ligand adopt the
same orientation as the phenylalanines of the Ab42 protein, it is
difficult to target the histidines in the Ab42 protein with a non-
peptide side-chain in the hybrid ligand. Rather, the side-chain
bends away such that the sulfate groups interact with Lys15 of
the Ab42 protein backbone, rather than with His13 or His14
(Fig. S2). Interestingly, during further molecular modeling
simulations it became apparent that the hybrid ligands could be
fully incorporated into the b-sheet structure of aggregated Ab
(Fig. S3), explaining why our hybrid ligands exerted no effect on
Ab aggregation and toxicity.
It is thought that BSB peptides, such as Ac-LPFFD-NH2 (7),
interfere with electrostatic interactions during aggregation or
destabilize the Ab-fibril internal hydrogen bond network,
necessary to maintain the b-sheet structure, by forming strong
hydrogen bonds with the Ab subunits.30 During the calculations
we were solely focused at the optimization of the affinity of the
sulfonylated hybrid ligands to the Ab protein. The disadvantage
of these compounds, however, is that because of this high quality
binding, it is very likely that we have designed compounds that
incorporate into the b-sheet structure of Ab42 aggregates, rather
than inhibiting aggregation of the protein, due to restoring the
Ab fibril internal hydrogen bond network (Fig. S3). Thus, to be
an effective BSB ligand, hybrid ligands should not only have
a higher binding affinity to the Ab42 protein, but should also
disrupt the b-sheet structure. Therefore, to optimize the ligands,
a ‘‘bulky’’ sidechain/group could be introduced to optimize our
hybrid ligands, thereby preventing its incorporation into the b-
sheet structure of Ab42. An alternative strategy involves changing
the amino acid sequence by replacing, for instance, one of the
phenylalanines by a polar amino acid and/or reducing hydrogen
bond interactions of the hybrid ligand with a next Ab protein.
In conclusion, a hybrid ligand with improved characteristics
with respect to inhibition of Ab fibrillization and Ab-mediated
cytotoxicity compared to Ac-LPFFD-NH2 (7)
10,14 was not found.
However, as our molecular modeling experiments suggest, the
designed hybrid ligands likely have a higher binding affinity for
Ab, but cannot avoid further aggregation of the Ab protein.
Changing the amino acid sequence by replacing, for instance, one
of the phenylalanines by a polar amino acid and/or reducing
hydrogen bond interactions of the hybrid ligand with a next Ab
protein could be a variable for optimization of the hybrid ligands
in future studies to validate the hypothesis that hybrid ligands
targeting Ab fibrillization by a combination of peptide-peptide
and sulfate-peptide interactions have enhanced properties.
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